AVXL
Anavex Life Sciences
stockNASDAQ
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson's disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.11 | 2026-11-05 | -11.06% | 3.178 |
| 1M | 1.51 | 2026-10-12 | -34.62% | 2.543 |
| 3M | 3.41 | 2026-08-12 | -71.05% | 2.129 |
| 6M | 3.06 | 2026-05-12 | -67.74% | 2.089 |
| 1Y | 6.90 | 2025-11-12 | -85.69% | 2.133 |
| 2Y | 9.02 | 2024-11-12 | -89.06% | — |
| 5Y | 22.39 | 2021-11-12 | -95.59% | 1.724 |
Anavex Life Sciences (NASDAQ:AVXL) stock price today is $0.99, and today's volume is 1,145,859. AVXL is down 6.868% today. The 30 day average volume is 1.28M. AVXL market cap is $91.51M with 92.70M shares outstanding.